Extramedullary disease in multiple myeloma - controversies and future directions
Jazyk angličtina Země Anglie, Velká Británie Médium print-electronic
Typ dokumentu časopisecké články, práce podpořená grantem, přehledy
PubMed
31005420
DOI
10.1016/j.blre.2019.04.002
PII: S0268-960X(18)30096-1
Knihovny.cz E-zdroje
- Klíčová slova
- Biomarker, Extramedullary disease, Multiple myeloma, Resistance, Treatment,
- MeSH
- lidé MeSH
- mnohočetný myelom komplikace patologie MeSH
- Check Tag
- lidé MeSH
- Publikační typ
- časopisecké články MeSH
- práce podpořená grantem MeSH
- přehledy MeSH
Extramedullary disease of multiple myeloma (EM) remains a treatment challenge even in the era of new drugs. While many reports analyzing various aspects of EM have been published, mechanism of EM development has not been clarified yet. This review summarizes current knowledge about this clinical entity, including its history, diagnostics, imaging methods, incidence, prognosis, current treatment options, risk factors and known molecular mechanisms that might be involved in pathogenesis of EM.
Department of Internal Medicine Hematology and Oncology University Hospital Brno Brno Czech Republic
Citace poskytuje Crossref.org
Del(1p32) is an early and high-risk event in multiple myeloma patients with extraosseous disease
Unexpected Heterogeneity of Newly Diagnosed Multiple Myeloma Patients with Plasmacytomas
Identification of patients at high risk of secondary extramedullary multiple myeloma development
Limited efficacy of daratumumab in multiple myeloma with extramedullary disease
A rare case of bifocal, extramedullary and hyposecretory relapse of multiple myeloma
Natural Killer Cells in the Malignant Niche of Multiple Myeloma